Yazar "Selvi, Oğuzhan" için listeleme
-
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
İlhan, Yusuf; Tatlı, Ali Murat; Teker, Fatih; Önder, Arif Hakan; Köse, Fatih; Geredeli, Çağlayan; Karaağaç, Mustafa; Kaplan, Muhammet Ali; İnanç, Mevlüde; Göktaş Aydın, Sabin; Kargı, Ayşegül; Arak, Hacı; Özturk, Banu; Beşen, Ali Ayberk; Selvi, Oğuzhan; Korkmaz, Mustafa; Oruç, Zeynep; Bozkurt, Oktay; Bilici, Ahmet; Bayram, Selami; Dae, Shute Ailia; Özdoğan, Mustafa; Coşkun, Hasan Şenol; Sezgin Göksu, Sema (BMJ Publishing Group, 2022)OBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In ... -
Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study
Atcı, Muhammed Mustafa; Akagündüz, Baran; Demir, Metin; Dönmez Yılmaz, Binnur; Akın Telli, Tuğba; Can, Orçun; Çil, İbrahim; Göktaş Aydın, Sabin; Özyurt, Neslihan; Önder, Arif Hakan; Selvi, Oğuzhan; Sakin, Abdullah (NLM (Medline), 2022)INTRODUCTION: A significant proportion of cervical cancer (CC) patients are diagnosed at a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the cornerstone of treatment for patients with locally advanced CC. ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Köse Baytemur, Naziyet; Yılmaz, Funda; Selvi, Oğuzhan; Hacıbekiroğlu, İlhan (BMC, 2023)Following publication of the original article [1], the authors reported an error in the author name of Enes Erul.